Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.73 |
| ▸ | KDM1A | O60341 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885509 | 1.00 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL12438756 | 0.90 | HDAC1 (0.68) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| Hydrochloric Acid SCHEMBL1889091 | 0.89 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| Hydrochloric Acid SCHEMBL1889089 | 0.89 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL8452272 | 0.89 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| Hydrochloric Acid SCHEMBL1888629 | 0.88 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| Hydrochloric Acid SCHEMBL1888631 | 0.88 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL3132141 | 0.88 | HDAC1 (0.58) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL3132128 | 0.88 | HDAC1 (0.58) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL3140824 | 0.88 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815855-B2 | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | 4SC AG (DE) | 2014-08-26 | — | — | US | claimed |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | MAIER THOMAS | 2010-03-25 | — | — | US | claimed |
| US-7666868-B2 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | 4SC AG (DE) | 2010-02-23 | — | — | US | claimed |
| EP-1861365-B1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-07-01 | — | — | EP | claimed |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | NYCOMED GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | claimed |
| US-12285410-B2 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2025-04-29 | — | — | US | disclosed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| WO-2021064188-A1 | COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-04-08 | — | — | WO | disclosed |
| EP-3781159-A1 | COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-7666868-B2 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | 4SC AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-2100878-A1 | Novel method for the production of sulphonylpyrroles as HDAC inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100878-A1 | Novel method for the production of sulphonylpyrroles as HDAC inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1861365-B1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | NYCOMED GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | HDAC1 14/4885HDAC3 13/4885HDAC2 16/4885 |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | HDAC1, H1-3, HDAC2 | HDAC1 1/4885HDAC3 11/4885HDAC2 3/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 4/4885HDAC2 8/4885 |
| US-12285410-B2 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 4/4885HDAC2 8/4885 |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC3 2/4885HDAC2 3/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC3 2/4885HDAC2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.